Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

as grindeks - metformina e sitagliptina - metformina e sitagliptina

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

adamed s.r.l. - metformina e sitagliptina - metformina e sitagliptina

Європейський Союз - італійська - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabete mellito, tipo 2 - farmaci usati nel diabete - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 e 5. 1 per i dati disponibili su diverse combinazioni).

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

bruno farmaceutici s.p.a. - metformina e sitagliptina - metformina e sitagliptina

Європейський Союз - італійська - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabete mellito, tipo 2 - farmaci usati nel diabete - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. , triplice terapia di associazione) in aggiunta alla dieta e all'esercizio fisico in pazienti non adeguatamente controllati il loro dosaggio massimo tollerato di metformina ed una sulfonilurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - metformina e sitagliptina - metformina e sitagliptina

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

doc generici srl - metformina - metformina

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

bayer s.p.a. - antiacidi - antiacidi

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

eg s.p.a. - metformina - metformina

Італія - італійська - AIFA (Agenzia Italiana del Farmaco)

zentiva italia s.r.l. - metformina e sitagliptina - metformina e sitagliptina